Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 13.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 379,650 shares of the company's stock after acquiring an additional 46,375 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.74% of Spyre Therapeutics worth $8,838,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Spyre Therapeutics in the fourth quarter valued at approximately $46,000. Rhumbline Advisers increased its stake in shares of Spyre Therapeutics by 6.9% in the 4th quarter. Rhumbline Advisers now owns 57,657 shares of the company's stock worth $1,342,000 after acquiring an additional 3,722 shares during the last quarter. Quest Partners LLC raised its holdings in shares of Spyre Therapeutics by 271.2% during the 3rd quarter. Quest Partners LLC now owns 5,654 shares of the company's stock worth $166,000 after acquiring an additional 4,131 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Spyre Therapeutics by 15.0% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 43,460 shares of the company's stock valued at $1,278,000 after acquiring an additional 5,678 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Spyre Therapeutics by 29.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 29,473 shares of the company's stock valued at $867,000 after acquiring an additional 6,701 shares during the last quarter. 80.39% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Spyre Therapeutics Stock Down 6.3 %

NASDAQ:SYRE traded down $1.14 on Wednesday, reaching $17.02. 784,492 shares of the company's stock were exchanged, compared to its average volume of 549,048. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -2.28 and a beta of 2.98. The business has a fifty day moving average of $20.75 and a 200-day moving average of $25.79. Spyre Therapeutics, Inc. has a 52-week low of $16.94 and a 52-week high of $40.84.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.08. As a group, equities analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on SYRE shares. The Goldman Sachs Group raised shares of Spyre Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 18th. Wolfe Research initiated coverage on shares of Spyre Therapeutics in a research report on Tuesday, March 18th. They set an "outperform" rating and a $27.00 price target on the stock. Finally, Wedbush reiterated an "outperform" rating and issued a $65.00 price objective on shares of Spyre Therapeutics in a report on Monday, January 13th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Spyre Therapeutics currently has an average rating of "Buy" and an average target price of $50.86.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).